Study of durvalumab for advanced liver cancer not treatable by surgery
Part of Cancer clinical trials.
This trial tests the drug durvalumab in people with advanced liver cancer (HCC) that has spread beyond the liver and cannot be removed by surgery. It aims to see if durvalumab can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a type of liver cancer called HCC that has spread beyond the liver and cannot be treated with surgery.
- You must have a tumor that can be measured on a scan (at least 1 cm across).
- You must have a liver biopsy confirming HCC within the last 3 months or be willing to have one.
- You must have good enough liver function (Child-Pugh score A or B7) and be able to care for yourself (ECOG 0-2).
- If you could become pregnant, you must agree to use effective birth control or be abstinent during treatment and for 3 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
This trial tests a new drug called RBS2418 added to two immunotherapy medicines (tremelimumab and durvalumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if the combination helps patients who are starting their first treatment for this stage of liver cancer.
This study is looking for people with advanced liver cancer (hepatocellular carcinoma) who have not yet had systemic treatment. Participants will receive a combination of two immunotherapy drugs: tremelimumab and durvalumab (the STRIDE regimen). The goal is to find biomarkers that can predict how well the cancer responds to this treatment.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
This study tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help control hepatocellular carcinoma (liver cancer) after you receive palliative, targeted radiation. It especially focuses on people whose cancer continued to grow after, or without, certain prior immune therapies.
Hear when a new Hepato Cellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.